CoChat

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Open access
Sikirica, Mirko, Martin, Alan, Wood, Robert, Leith, Andrea, Piercy, James, Higgins, Victoria · 2017 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

AIM: Nonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs. MATERIALS AND METHODS: Retrospective data from the Adelphi Diabetes Disease Specific Programme were used. Physicians managing patients with T2DM were surveyed via face-to-face interviews, and patients treated for T2DM were surveyed via self-completed questionnaires. Patient data were stratified by current versus prior GLP1 RA use. RESULTS: Physicians (n=443) most frequently reported inadequate blood glucose control (45.6%), nausea/vomiting (43.8%), and gastrointestinal (GI) side effects (36.8%) as reasons for GLP1 RA discontinuation. Patients (n=194) reported the GI-related issues "Made me feel sick" (64.4%) and "Made me throw up" (45.4%) as their top reasons for discontinuation. The most common problems reported (excluding cost) for those currently using GLP1 RAs were "Prefer oral medication over injections" (patients 56%, physicians 32.6%), "Made me feel sick" (patients 38.1%, physicians 16.3%), and "Did not help lose weight" (patients 25.4%, physicians 18%). The most bothersome problems for patients globally (frequency reporting very/extremely bothersome) (excluding cost) were "Difficult to plan meals around" (55.6%), "Made me throw up" (51.6%), and "Caused weight gain" (50%). CONCLUSION: Both patients and physicians reported GI-related issues as a prominent factor, but disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician-patient communication. Understanding patients' expectations of GLP1 RAs and physicians' patient-management practices may help increase GLP1 RA adherence and thereby potentially enhance diabetes care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dmso.s141235

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient-survey cohort (n=2,173). Notes: Bases for each analysis differ based on the number of responses for question. Abbreviations: GLP1 RA, glucagon-like peptide-1 receptor agonist; T2DM, type 2 diabetes mellitus.
Figure 1 Patient-survey cohort (n=2,173). Notes: Bases for each analysis differ based on the number of responses for question. Abbreviations: GLP1 RA, glucagon-like peptide-1 receptor agonist; T2DM, type 2 diabetes mellitus.CC BY-NC · PubMed Central
Figure 2 Reasons for GLP1 RA discontinuation in the past 6 months, ranked by frequency. Notes: (A) Physicians (n=443); (B) patients (n=194). Abbreviations: GI, gastrointestinal; GLP1 RA, glucagon-like peptide-1 receptor agonist.
Figure 2 Reasons for GLP1 RA discontinuation in the past 6 months, ranked by frequency. Notes: (A) Physicians (n=443); (B) patients (n=194). Abbreviations: GI, gastrointestinal; GLP1 RA, glucagon-like peptide-1 receptor agonist.CC BY-NC · PubMed Central
Figure 3 Problems reported with GLP1 RA treatment. Notes: *GI-related issues. Physician-estimated versus patient-reported prevalence of each problem among patients currently using GLP1 RAs. (A) Global results; (B) EU5 results (France, Germany, Italy, Spain, and the UK); (C) US results; (D) global results, proportion of patients reporting problems as very or extremely bothersome. Exact questions listed in Table S1. Abbreviations: GI, gastrointestinal; GLP1 RA, glucagon-like peptide-1 receptor agonist.
Figure 3 Problems reported with GLP1 RA treatment. Notes: *GI-related issues. Physician-estimated versus patient-reported prevalence of each problem among patients currently using GLP1 RAs. (A) Global results; (B) EU5 results (France, Germany, Italy, Spain, and the UK); (C) US results; (D) global results, proportion of patients reporting problems as very or extremely bothersome. Exact questions listed in Table S1. Abbreviations: GI, gastrointestinal; GLP1 RA, glucagon-like peptide-1 receptor agonist.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

Items 101–200 of 234

Metadata

Authors
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V.
Affiliations
  • GlaxoSmithKline (United States) (US)
  • GlaxoSmithKline (United Kingdom) (GB)
  • Adelphi Group (United Kingdom) (GB)
Corresponding author
Sikirica, Mirko
Venue
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Published
2017-09
Volume
Volume 10
Pages
403-412
ISSN
1178-7007 (ISSN-L)
OpenAlex
W2763255780
Cited by
223
References
21
Citations by year
2026: 40 · 2025: 54 · 2024: 34 · 2023: 23 · 2022: 21 · 2021: 22 · 2020: 13 · 2019: 11 · 2018: 5
FWCI
6.27
Type
journal article
Language
en
Open access
Locations
  • Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
GLP-1 receptor agonists, type 2 diabetes, drug discontinuation, medication adherence, gastrointestinal adverse effects, nausea and vomiting, physician-patient communication, patient expectations, weight gain, physician perceptions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.